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implantation in a hemodynamically unstable infant
with ventricular tachycardia from multiple cardiac
rhabdomyomas
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James A. Quintessenza, MD,*† Roosevelt Bryant III, MD,† ShaunMohan, MD, MPH, FHRS*
From the *Kentucky Children’s Hospital, University of Kentucky, UK Healthcare, Lexington, Kentucky, and
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Introduction
Tuberous sclerosis complex (TSC) is a neurocutaneous disor-
der characterized by benign tissue hamartomas in multiple
organ systems, including cardiac rhabdomyomas.1 Though
prevalent in TSC, cardiac tumors are rare in children, occur-
ring in about 0.03%–0.17%. Rhabdomyomas are the most
common, accounting for 45%.2,3 When present, they are
multiple and in the ventricular myocardium.4 Frequently,
they regress and surveillance is all that is required until spon-
taneous regression.5 Intervention is necessary when life-
threatening obstruction or hemodynamically significant
refractory arrhythmias occur. This case highlights the course
of a 6-month-old infant with TSC and cardiac rhabdomyomas
who presented in refractory ventricular tachycardia (VT)
with decompensation and cardiac arrest necessitating venoar-
terial extracorporeal membrane oxygenation (VA-ECMO),
complex antiarrhythmic therapy, and ultimately implantable
cardioverter-defibrillator (ICD) implantation.
Case report
Our patient was found to have intracardiac tumors by a fetal
echocardiogram at 34 weeks gestation. Postpartum, an echo-
cardiogram and electrocardiogram (ECG) were completed.
The ECG showed normal sinus rhythm with normal intervals
and voltages, with J point and ST elevation in the inferolateral
leads, consistent with benign early repolarization. His echo-
cardiogram confirmed multiple rhabdomyomas along the
interventricular septum and left ventricular myocardium, and
in the anterior outlet septum extending into the right
ventricular outflow tract, but without inflow or outflow
obstruction of either ventricle (Figure 1). Additionally, a
head ultrasound was concerning for intracranial tumors. These
findings raised high suspicion for TSC and he was referred for
further testing. He developed infantile spasms and was started
on vigabatrin for management. At 3 months of age, his ECG
was unchanged and echocardiogram displayed minimal
regression of the tumors. At that visit, a 6-month cardiac
follow-up with repeat testing was recommended.
At 6 months of age, he awoke from a nap crying and lost
consciousness and motor tone for 2 minutes, described as
“unlike his infantile spasms.” On emergency medical ser-
vices arrival, he was alert but upset. A cardiac monitor re-
vealed a wide complex tachycardia (WCT) with a heart rate
.300 beats per minute (bpm). At the local emergency depart-
ment he was given 3 doses of adenosine (single dose of 0.1
mg/kg and 2 doses of 0.2 mg/kg), without any effect on the
WCT. His ECG (Figure 2) was consistent with monomorphic
VT and an esmolol infusion (50 mcg/kg/min) was initiated at
the recommendation of the on-call pediatric cardiologist. The
patient was then transferred to our center and during transport
remained stable on room air with appropriate capillary refill
(,2 seconds). Upon arrival, an emergent echocardiogram
showed no evidence of obstruction or pericardial effusion,
with inability to comment on systolic function secondary to
the heart rate. He remained in VT at 280–330 bpm and his es-
molol drip was titrated to 150 mcg/kg/min. An additional
dose of adenosine (0.2 mg/kg) was administered without
notable change. He received 7 mg of ketamine and 7 mg of
rocuronium. Calcium chloride (100 mg) was given prior to
an amiodarone bolus (5 mg/kg) in an attempt to chemically
cardiovert the rhythm. His rhythm suddenly deteriorated
into ventricular fibrillation (VF) and cardiopulmonary resus-
citation was initiated. Two 15 J shocks were administered
with conversion to sinus, but rhythm immediately reverted
back into VT with a palpable pulse. He was intubated and
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placed on a ventilator. His perfusion worsened, with evidence
of cardiogenic shock. The decision was made to place him on
VA-ECMO for continued support (flow started at 100 mL/
kg). After cannulation, he went into VF (total time about 5
minutes after full extracorporeal membrane oxygenation
[ECMO] flows) and was defibrillated with 15 J and success-
fully cardioverted to sinus rhythm.
Once cardioverted, he was cooled and placed on morphine
and dexmedetomidine infusions to decrease metabolic
demand. A repeat echocardiogram showed severely reduced
biventricular systolic function, prompting initiation of cal-
cium chloride (5 mg/kg/hr) and milrinone (0.5 mcg/kg/
min). He was loaded with oral amiodarone through a naso-
gastric tube at 20 mg/kg/day with frequent ECG monitoring.
His mean arterial pressures (MAP) increased, necessitating a
nitroprusside (0.3 mcg/kg/min) drip. Ventricular function
improved over 1–2 days and his MAPs normalized, allowing
transfer to the nearest quaternary children’s hospital for
further management. After transfer, he had another episode
of sustained monomorphic VT that responded to synchro-
nized cardioversion and was maintained on esmolol. The
following day, he had increasing amounts of premature ven-
tricular contractions and nonsustained VT and was transi-
tioned to a lidocaine infusion (20 mcg/kg/min) without
additional ensuing events. He was decannulated on his third
hospital day and started on mexiletine with plans to wean him
off his lidocaine infusion over 1 week. However, he
continued to have breakthrough VT while on mexiletine
(15 mg/kg/day) and amiodarone, as the amiodarone mainte-
nance dose was decreased to 5 mg/kg/day. After discussion
with surgeons, intensivists, and electrophysiologists, he
underwent placement of a dual-chamber epicardial ICD.
At the time of ICD implantation (Medtronic Evera, Min-
neapolis, MN), our patient was 7.7 kg and 70 cm. Bipolar
25-cm steroid-eluting leads (Medtronic 4968) were sutured
to the epicardial surface of the right atrial appendage and
left ventricular apex with the ICD coil (Medtronic 6937A)
placed in the pericardium and oriented for a ventricular vector
from the left superior aspect of the pericardium, similar to a
previously reported case.6 The generator was positioned in
the right upper quadrant, beneath the anterior rectus sheath,
where the leads and coil were tunneled (Figure 3). The ICD
was programmed with a VF zone at 270 ms, fast VT at 250
ms, and slow VT at 320 ms. Detection was programmed
with initial 30/40 beats and redetect at 12/16 beats. Antita-
chycardia pacing (ATP) was programmed in burst mode
with 8 pulses at 81% of the tachycardia cycle length. Five
shocks were programmed at 1 J, 10 J, 20 J, 20 J, and 20 J.
No therapies were programmed for slow VT. The pacing pa-
rameters were AAI-DDD with lower rate limit of 60 bpm and
upper tracking rate of 150 bpm.
After the procedure, he had further episodes of sustained
VT that successfully terminated with ICD shocks. His mex-
iletine was discontinued and transitioned to oral flecainide.
Subsequent episodes of VT all terminated with pacing and
very low energy shocks (0.4 J) with his device after transition
to flecainide. After this medication change, the fast VT zone
(via VF) was changed to 210 ms. This would allow the device
to treat any arrhythmia 222–286 bpm with ATP for 1 round,
as it would be classified as fast VT. Afterward, shocks at 0.4
J, 1 J, 10 J, 15 J, and 20 J would be delivered if it did not
terminate. Above 286 bpm, the device would treat the
arrhythmia in this zone as VF and administer 3 rounds of
ATP. Shocks would then be delivered at 0.4 J, 1 J, 5 J, 10
J, and 20 J if the arrhythmia was classified in this zone.
The delivered energy dosage was chosen to deliver the lowest
dosage allowable (0.4 J) initially and then in escalating
dosage in the event of defibrillation failure. With titration
of flecainide to 5 mg/kg/day and an amiodarone dose of 5
mg/kg/day, he has remained stable, free from recurrent VT.
At his last postdischarge follow-up visit, at 9 months of
age, he has continued to do well, with a reassuring repeat
ECG showing sinus rhythm without ECG signs of flecainide
toxicity or interval changes secondary to amiodarone.
Discussion
Cardiac tumors (even rhabdomyomas) are rare in children, and
they typically do not cause symptoms or hemodynamic
compromise in the majority of patients. However, they can
become symptomatic, depending on the number, position,
and size of the tumors. Some may obstruct flow and lead
to ventricular or valvular dysfunction with subsequent heart
failure. They may also compress or interrupt the conduction
system, leading to arrhythmia, heart block, sinus node
dysfunction, and/or preexcitation.5,7,8 In this report, we
detail a patient with rhabdomyomas with abrupt
development of significant arrhythmogenesis and
hemodynamic collapse. With aggressive treatment including
hemodynamic bridgingwith VA-ECMO, antiarrhythmic ther-
apy, and long-termprotectionwith an ICD, the patient was sta-
bilized and is doing well with outpatient management.
Miyake and colleagues9 reported a series of 106 rhabdo-
myoma cases in which hemodynamic changes were reported
KEY TEACHING POINTS
 Arrhythmias are a rare but known complication of
cardiac rhabdomyomas and require periodic
ambulatory rhythm surveillance, independent of
size or number of the tumors.
 Cardioversion/defibrillation is the indicated
treatment for unstable ventricular tachycardia and
requires forethought in regard to local resources to
support an unstable pediatric patient, should
cardiovascular collapse occur.
 Implantable cardioverter-defibrillator placement in
a pediatric patient requires a collaborative effort
between electrophysiologists and cardiothoracic
surgeons with expertise in pediatric patients, with
considerations of the limitations and long-term
complications of transvenous devices.
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in 17% of the children and significant arrhythmias were
found in 16%. These arrhythmias included VT (6%), ventric-
ular preexcitation with sustained supraventricular tachyardia
(SVT) (2%), ventricular preexcitation without SVT (8%),
and sustained SVT (5%) without underlying preexcitation.
Additionally, ventricular ectopic beats and couplets and brief
nonsustained SVT were found in 12% and various other
arrhythmias were found in 28% of the patients.9 Józwiak
and colleagues10 evaluated 154 patients with TSC and found
that of the 74 with cardiac rhabdomyomas, the main clinical
manifestations of the tumors that did not remain silent or
regress were arrhythmias (23%), murmurs (14.9%), and heart
failure (5.4%).
Based on published literature, arrhythmia remains the
most common symptomatic cardiac manifestation in individ-
uals with TSC. Frequently, they are successfully treated with
antiarrhythmic medications as an adjunct to careful follow-
up, with eventual tumor regression, as seen in a retrospective
single-center study conducted from 1968 to 2010.9 Our
patient presented with sustained intractable monomorphic
VT that culminated in cardiac arrest from degeneration into
VF. His management required early recognition of his
Figure 2 Electrocardiogram on initial hospital presentation via arrival by emergency medical services.
Figure 1 Postnatal echocardiogram showing multiple intramyocardial masses along the interventricular septum (parasternal short-axis view) and on the left
ventricular free wall (apical view).
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rhythm and transfer to a center with pediatric subspecialty
care. With intensive care, defibrillation on VA-ECMO,
numerous antiarrhythmic medications, and epicardial ICD
implantation, the child was able to survive and is doing
well in follow-up.
The workup of wide complex tachycardia can be chal-
lenging in young patients, particularly if hemodynamically
tenuous. Pediatric patients can have extremely fast ventricu-
lar rates compared to adults, and the QRS complexes may not
be recognized as wide by standard ECG machines or pro-
viders who are unfamiliar with pediatric ECGs. The majority
of wide complex tachycardias in pediatric patients are due to
aberrant SVT, and therefore adenosine is part of the Pediatric
Acute Life Support algorithm for wide complex tachycardia
if the patient is stable.11 The ECG showed right bundle
branch morphology with an inferior axis that is also right-
ward (negative in leads I and aVL), suggesting the VT was
from the left ventricular outflow tract. There was no concor-
dance in the precordial leads to make VT more likely, but
using the aVR criteria, there is an initial R wave that made
VT more likely. The historic clues to making the diagnosis
were knowing the patient had a normal ECG at 2 months
of age and he had significant rhabdomyomas in his ventricu-
lar myocardium. With no change in tachycardia cycle length
or QRS morphology with adenosine administration, VT was
the most likely rhythm.
The mechanism of the VT was presumed to be triggered
activity as well as reentry, but not definitively proven. After
defibrillation (prior to ECMO cannulation), the patient would
shortly revert back into VT after a sinus beat. After placement
of the ICD, the tachycardia would terminate with ATP in the
ventricle, supporting reentry as a contributing mechanism.
The patient’s history and known presence of rhabdomyomas
in the ventricles made verapamil-sensitive (fascicular) VT
unlikely.
This is the first report of hemodynamically significant VT
due to cardiac rhabdomyomas in a pediatric patient leading to
VA-ECMO and ICD implantation. The natural history of
these tumors would suggest that observation is prudent in
most cases; however, our patient required significant antiar-
rhythmic therapy and an ICD owing to his arrest from VT.
The patient’s case was discussed at our combined surgical/
cardiology conference after he was on ECMO and transferred
to a pediatric quaternary center where we have an established
partnership for care of patients. Tumor resection was not an
option owing to the extensive nature of the masses and exten-
sion into the crux of the heart and proximity to the coronary
arteries. Resection of the left ventricular free wall was not
feasible. Antitumor medications, such as sirolimus,12–14
were considered, but the duration of treatment would be
long and there was no guarantee a smaller tumor would
equate to less or no VT. The risks of ICD implantation in a
young patient were weighed carefully (frequent shocks as
well as inappropriate shocks, infection risk, and future
invasive procedures for generator changes/lead revisions).
Transplantation was considered, but he was weaned
successfully from ECMO and the decision was made to
place an ICD after all possible options were considered.
For now, the patient is doing well and thriving on flecai-
nide and amiodarone with close outpatient monitoring.
Knowing that patients with TSC and cardiac rhabdomyomas
can have life-threatening arrhythmias, it is worth considering
more frequent ambulatory outpatient monitoring with
pediatric cardiologists or electrophysiologists to survey for
life-threatening rhythms. If sustained arrhythmias are seen,
intervention might be warranted sooner than careful observa-
tion and waiting for regression of the masses.
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